Ayunova Pharmaceutical LLP

Nilotinib Tablets BP – 200 mg

Nilotinib 200 mg Tablets BP is a second-generation tyrosine kinase inhibitor (TKI) used for the treatment of Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML).

Nilotinib is designed to selectively and potently inhibit BCR-ABL tyrosine kinase, including many imatinib-resistant mutations, thereby blocking abnormal cancer cell signaling and proliferation. It provides rapid, deep molecular responses and is widely used as first-line or second-line therapy in CML patients.

Each hard gelatin capsule/tablet contains:

• Nilotinib BP – 200 mg

• Excipients: q.s. (pharmaceutical grade)

Nilotinib Tablets are indicated for:

1. Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML)

   • Newly diagnosed chronic phase CML

   • CML patients resistant or intolerant to prior therapy, including imatinib

1. Chronic and accelerated phase CML

2. Second-line therapy where first-generation TKIs are ineffective

3. Achieving rapid molecular and cytogenetic response

• Usual adult dose: 400 mg twice daily (2 × 200 mg) or as prescribed

• Must be taken on an empty stomach

  • No food 2 hours before and 1 hour after dosing

• Swallow whole with water; do not crush or chew

• Therapy to be continued under oncologist supervision

• Blister packs: 10 capsules/tablets per strip

• Institutional and bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 120 tablets

Lenalidomide Tablets BP – 25 mg

Lenalidomide 25 mg Tablets BP is an immunomodulatory and anticancer agent used in the treatment of multiple myeloma and other hematological malignancies.

Lenalidomide works through multiple mechanisms, including modulation of the immune system, inhibition of angiogenesis, and direct antitumor activity. It enhances T-cell and NK-cell function, leading to suppression of malignant cell growth.

This oral formulation provides potent efficacy, convenient dosing, and improved survival outcomes, making it a key medicine in modern hematology and oncology practice.

Each hard gelatin capsule/tablet contains:

• Lenalidomide BP – 25 mg

• Excipients: q.s. (pharmaceutical grade)

Lenalidomide Tablets are indicated for:

1. Multiple Myeloma

   • In combination with dexamethasone in newly diagnosed or relapsed patients

2. Myelodysplastic Syndromes (MDS)

   • With deletion 5q cytogenetic abnormality

1. Mantle Cell Lymphoma (MCL)

   • In patients whose disease has relapsed or progressed after prior therapy

2. Follicular Lymphoma and Marginal Zone Lymphoma

   • In combination regimens as prescribed

• Typical dose: 25 mg once daily on Days 1–21 of a 28-day cycle (as prescribed)

• Taken orally with or without food

• Capsules/tablets should be swallowed whole; do not break or chew

• Therapy must be managed under specialist supervision

• Blister packs: 10 capsules/tablets per strip

• Institutional and bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 25 mg

Sunitinib Tablets BP – 50 mg

Sunitinib 50 mg Tablets BP is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of advanced renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET).

Sunitinib works by inhibiting multiple receptor tyrosine kinases, including VEGFR, PDGFR, c-KIT, and FLT3, which are involved in tumor angiogenesis and cell proliferation. This targeted mechanism allows for effective management of metastatic or unresectable cancers while providing convenient oral dosing.

Each film-coated tablet contains:

• Sunitinib BP – 50 mg

• Excipients: q.s. (pharmaceutical grade)

Sunitinib Tablets are indicated for:

1. Advanced Renal Cell Carcinoma (RCC)

2. Gastrointestinal Stromal Tumors (GIST)

   • For patients resistant or intolerant to imatinib therapy

3. Pancreatic Neuroendocrine Tumors (pNET)

1. Inhibition of tumor angiogenesis

2. Management of metastatic or unresectable tumors

• Standard adult dose: 50 mg orally once daily for 4 weeks, followed by 2 weeks off (6-week cycle) or as prescribed

• Tablets should be taken on an empty stomach

• Swallow whole with water; do not crush or chew

• Dose adjustments may be required in hepatic impairment or adverse reactions

• Blister packs: 10 tablets per strip

• Bulk / institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 100000
• Delivery Time: 10 days
• Packaging Details: 50 mg

Carboplatin for Injection BP

Carboplatin for Injection BP is a platinum-based antineoplastic (chemotherapy) agent widely used in the treatment of solid tumors and advanced cancers. It acts by forming DNA cross-links, inhibiting DNA replication and transcription, and ultimately inducing cancer cell apoptosis.

Carboplatin is a second-generation platinum compound, designed to reduce the nephrotoxicity and gastrointestinal side effects associated with cisplatin while maintaining strong anticancer efficacy. It is commonly used in combination chemotherapy regimens, especially for gynecological, lung, and head-and-neck cancers, and is administered intravenously under specialist oncology supervision.

Each vial contains:

• Carboplatin BP – 150 mg / 300 mg / 450 mg / 600 mg

• Excipients: q.s. for injection (sterile lyophilized powder or solution)

• Ovarian Cancer – first-line and recurrent treatment

• Non-Small Cell and Small Cell Lung Cancer

• Testicular Cancer – as part of combination chemotherapy

• Head and Neck Cancer

• Bladder Cancer

• Cervical Cancer

• Endometrial Cancer

• Gastrointestinal Cancers (stomach, esophagus)

• Combination chemotherapy protocols (e.g., Carboplatin + Paclitaxel, Carboplatin + Etoposide)

• Palliative treatment in advanced malignancies

• Alternative for patients intolerant to cisplatin

• Route: Intravenous infusion only

• Dose: Calculated using the Calvert formula (mg = target AUC × [GFR + 25]) or per treatment protocol

• Administration: Diluted in suitable IV fluids, infused slowly over 30–60 minutes

• Monitoring: Renal function, hematological parameters, and electrolytes

⚠ Administer only under experienced oncology supervision

• Available strengths: 150 mg, 300 mg, 450 mg, 600 mg vials

• Sterile lyophilized powder or solution for injection

• Institutional and hospital packaging available

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 450mg

Bleomycin for Injection BP

Bleomycin for Injection BP is an antineoplastic antibiotic derived from Streptomyces verticillus, used in chemotherapy for various malignancies. It works by binding to DNA and causing strand breaks, which inhibits DNA synthesis and induces apoptosis in rapidly dividing cancer cells.

This sterile injectable formulation is intended for intravenous, intramuscular, or subcutaneous administration under specialist supervision. Bleomycin is widely used in oncology hospitals, cancer centers, and specialty clinics for the management of solid tumors and certain hematological malignancies.

Each vial contains:

• Bleomycin Sulfate BP – 15 mg / 30 mg / 100 mg

• Excipients: q.s. sterile water for injection (lyophilized powder)

After reconstitution, it is ready for IV, IM, or SC administration.

• Hodgkin’s Lymphoma – as part of combination chemotherapy regimens (e.g., ABVD)

• Non-Hodgkin’s Lymphoma – selected treatment protocols

• Testicular Cancer – in combination with cisplatin and etoposide

• Squamous Cell Carcinoma – head, neck, and skin malignancies

• Gestational choriocarcinoma

• Combination chemotherapy for various solid tumors

• Adjunct therapy in multi-drug chemotherapy protocols

• Route: Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) injection

• Adult Dose: Typically 15 mg/m² IV/IM/SC per week, depending on regimen

• Pediatric Dose: Weight-based, adjusted per oncology protocol

• Monitoring: Pulmonary function, renal function, liver function, and hematologic parameters

⚠ Administer only under oncology specialist supervision

• Available strengths: 15 mg, 30 mg, 100 mg vials

• Lyophilized powder for injection

• Hospital and bulk packaging available

• Store 2–8°C (Refrigerated)

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 30 IU

Temozolomide Tablets BP – 250 mg

Temozolomide Tablets BP is an oral alkylating anticancer agent primarily used in the treatment of malignant brain tumors. It works by damaging tumor DNA, thereby inhibiting cancer cell replication and inducing apoptosis.

Temozolomide is widely used in neuro-oncology for both newly diagnosed and recurrent gliomas, often as part of combined chemoradiation therapy. Due to its oral administration and favorable CNS penetration, it is a preferred chemotherapy agent in brain cancer management.

Each tablet contains:

• Temozolomide BP – 250 mg

• Excipients: q.s.

• Glioblastoma multiforme (GBM)

  • Newly diagnosed GBM (concomitant with radiotherapy and as maintenance therapy)

  • Recurrent or progressive GBM

• Anaplastic astrocytoma

  • Refractory or relapsed cases after standard therapy

• High-grade gliomas

• Central nervous system (CNS) tumors

• Metastatic brain tumors (off-label, under specialist supervision)

• Route: Oral

• Administration: Taken on an empty stomach or as advised by an oncologist

• Dose: Determined based on body surface area (mg/m²), treatment phase, and clinical condition

• Treatment Cycle: Usually given in 5-day cycles every 28 days

⚠ Strictly to be used under oncologist supervision
⚠ Blood counts must be monitored regularly

• Blister / strip packing

• Bottle packing (as per requirement)

• Export and hospital bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 250 mg

Niraparib Tablets BP – 300 mg

Niraparib Tablets BP is an oral Poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of recurrent and advanced ovarian cancer and other homologous recombination deficiency (HRD)–positive malignancies.

Niraparib works by inhibiting PARP-1 and PARP-2 enzymes, leading to accumulation of DNA damage in cancer cells and ultimately tumor cell death, especially in tumors with BRCA mutations or DNA repair defects. It is widely used as first-line and maintenance therapy after platinum-based chemotherapy.

Each film-coated tablet contains:

• Niraparib BP – 300 mg

• Excipients: q.s.

• Maintenance treatment of recurrent epithelial ovarian cancer

• First-line maintenance therapy for advanced ovarian cancer

• Platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer

• BRCA-mutated ovarian cancer

• HRD-positive ovarian cancer regardless of BRCA status

• Maintenance therapy following response to platinum-based chemotherapy

• Targeted treatment in homologous recombination-deficient tumors

• Route: Oral

• Usual Dose: 300 mg once daily or as prescribed by an oncologist

• Administration: Can be taken with or without food

⚠ Dose adjustments may be required based on body weight and platelet count
⚠ Regular monitoring of blood counts and blood pressure recommended

• Blister packs / HDPE bottles

• Bulk and export-oriented packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 50000
• Delivery Time: 10 days
• Packaging Details: 120 tablets

Ribociclib Tablets BP – 400 mg

Ribociclib Tablets BP is an oral, selective Cyclin-Dependent Kinase (CDK) 4/6 inhibitor used for the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer.

Ribociclib inhibits CDK4 and CDK6, preventing phosphorylation of the retinoblastoma (Rb) protein, leading to cell-cycle arrest in the G1 phase and suppression of tumor cell proliferation. It is primarily used in combination with endocrine therapy to significantly improve progression-free survival.

Each film-coated tablet contains:

• Ribociclib BP – 400 mg

• Excipients: q.s.

• Hormone receptor-positive (HR+), HER2-negative advanced breast cancer

• Metastatic breast cancer in postmenopausal women

• First-line treatment in combination with aromatase inhibitors

• Treatment in combination with fulvestrant for patients with disease progression following endocrine therapy

• Recurrent breast cancer with endocrine sensitivity

• CDK4/6-dependent solid tumors (as directed by oncologist)

• Route: Oral

• Usual Dose: 400 mg once daily for 21 days followed by 7 days off (28-day cycle)

• Administration: Take with or without food, as prescribed

⚠ ECG monitoring required due to QT prolongation risk
⚠ Regular CBC and liver function monitoring recommended

• Blister strips / HDPE bottles

• Export and hospital packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 100000
• Delivery Time: 10 days
• Packaging Details: 120 tablets

Crizotinib Tablets BP – 250 mg

Crizotinib Tablets BP is an oral, targeted tyrosine kinase inhibitor used for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) harboring ALK (Anaplastic Lymphoma Kinase) or ROS1 gene rearrangements.

Crizotinib selectively inhibits ALK, ROS1, and MET tyrosine kinases, leading to suppression of tumor cell growth and survival. It provides significant clinical benefit in ALK-positive and ROS1-positive lung cancers, offering improved response rates and progression-free survival compared to conventional chemotherapy.

Each film-coated tablet contains:

• Crizotinib BP – 250 mg

• Excipients: q.s.

• ALK-positive non-small cell lung cancer (NSCLC)

• ROS1-positive advanced or metastatic NSCLC

• First-line targeted therapy for ALK-rearranged lung cancer

• Treatment of locally advanced or metastatic lung adenocarcinoma

• MET-amplified solid tumors (under oncologist supervision)

• Relapsed NSCLC after chemotherapy in ALK/ROS1-positive patients

• Route: Oral

• Usual Dose: 250 mg twice daily or as prescribed by oncologist

• Administration: With or without food

⚠ Regular liver function tests and ECG monitoring recommended
⚠ Visual disturbances and GI effects should be monitored

• Blister strips / HDPE bottles

• Export, institutional & hospital packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 120 tablets

Ceritinib Tablets BP – 150 mg

Ceritinib Tablets BP is an oral, next-generation tyrosine kinase inhibitor specifically designed for the treatment of Anaplastic Lymphoma Kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Ceritinib potently inhibits ALK tyrosine kinase, including many crizotinib-resistant ALK mutations, leading to effective tumor control. It is used both as first-line therapy and in patients who have progressed on or are intolerant to crizotinib.

Each film-coated tablet contains:

• Ceritinib BP – 150 mg

• Excipients: q.s.

• ALK-positive non-small cell lung cancer (NSCLC)

• Metastatic or locally advanced ALK-rearranged lung adenocarcinoma

• Treatment of NSCLC patients with disease progression after crizotinib therapy

• First-line targeted therapy for ALK-positive NSCLC

• ALK inhibitor therapy for crizotinib-resistant lung cancer

• Advanced solid tumors with ALK rearrangements (as directed by oncologist)

• Route: Oral

• Usual Dose: As prescribed by oncologist (commonly once daily with food)

• Administration: Take with food to improve tolerability

⚠ Regular monitoring of liver function, blood glucose, and heart rate recommended
⚠ Dose adjustment may be required based on adverse effects

• Blister strips / HDPE bottles

• Hospital, institutional & export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 120 tablets

Alectinib Tablets BP – 150 mg

Alectinib Tablets BP is an oral, highly selective Anaplastic Lymphoma Kinase (ALK) inhibitor used for the treatment of ALK-positive non-small cell lung cancer (NSCLC).

Alectinib potently inhibits ALK, including multiple crizotinib-resistant ALK mutations, and demonstrates excellent central nervous system (CNS) penetration, making it highly effective in patients with brain metastases. It is widely recommended as a preferred first-line therapy for ALK-positive advanced NSCLC.

Each film-coated tablet contains:

• Alectinib BP – 150 mg

• Excipients: q.s.

• ALK-positive non-small cell lung cancer (NSCLC)

• First-line treatment of metastatic ALK-rearranged lung cancer

• Treatment of NSCLC patients previously treated with crizotinib

• Advanced or locally advanced ALK-positive lung adenocarcinoma

• ALK-positive NSCLC with brain metastases

• Crizotinib-resistant ALK-rearranged lung cancer

• Route: Oral

• Usual Dose: 600 mg daily (150 mg tablets taken as prescribed, usually twice daily)

• Administration: Take with food for optimal absorption

⚠ Monitor liver function, CPK levels, and heart rate regularly
⚠ Dose modification may be required based on tolerability

• Blister strips / HDPE bottles

• Hospital, institutional & export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 120 tablets

Vandetanib Tablets BP – 100 mg

Vandetanib Tablets BP is an oral multi-targeted tyrosine kinase inhibitor (TKI) used primarily for the treatment of advanced and metastatic medullary thyroid carcinoma (MTC).

Vandetanib inhibits multiple receptor tyrosine kinases including RET (Rearranged during Transfection), VEGFR (Vascular Endothelial Growth Factor Receptor), and EGFR, thereby suppressing tumor growth, angiogenesis, and metastatic progression. It is a well-established targeted therapy for progressive or symptomatic medullary thyroid cancer.

Each film-coated tablet contains:

• Vandetanib BP – 100 mg

• Excipients: q.s.

• Advanced medullary thyroid carcinoma (MTC)

• Metastatic or unresectable medullary thyroid cancer

• Progressive or symptomatic MTC

• RET-mutated thyroid carcinoma

• Differentiated thyroid cancer resistant to radioiodine therapy (off-label, as directed by oncologist)

• Advanced solid tumors expressing RET or EGFR (under specialist supervision)

• Route: Oral

• Usual Dose: As prescribed by oncologist (dose adjustments based on tolerability and ECG findings)

• Administration: With or without food

⚠ ECG monitoring mandatory due to risk of QT interval prolongation
⚠ Monitor electrolytes, thyroid function, and blood pressure regularly

• Blister strips / HDPE bottles

• Hospital, institutional & export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 200000
• Delivery Time: 10 days
• Packaging Details: 120 tablets

Ixazomib Tablets BP – 2.3 mg

Ixazomib Tablets BP is an oral proteasome inhibitor used for the treatment of multiple myeloma in combination with lenalidomide and dexamethasone. It is the first oral proteasome inhibitor, offering convenient, effective, and long-term disease control in relapsed or refractory multiple myeloma.

Ixazomib inhibits the 20S proteasome, disrupting protein degradation in malignant plasma cells, leading to apoptosis and inhibition of tumor growth. Its oral formulation improves patient compliance while maintaining strong anti-myeloma efficacy.

Each hard capsule / tablet contains:

• Ixazomib BP – 2.3 mg

• Excipients: q.s.

• Multiple myeloma in patients who have received at least one prior therapy

• Relapsed or refractory multiple myeloma

• Combination therapy with lenalidomide and dexamethasone

• Maintenance therapy in multiple myeloma (as prescribed)

• Plasma cell dyscrasias (under specialist supervision)

• Route: Oral

• Usual Dose: 2.3 mg once weekly on Days 1, 8, and 15 of a 28-day cycle (dose adjusted by oncologist)

• Administration: Take on an empty stomach (at least 1 hour before or 2 hours after food)

⚠ Dose modification required in hepatic or renal impairment
⚠ Regular monitoring of platelet count and liver function recommended

• Blister packs / HDPE bottles

• Hospital, institutional & export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 120 tablets

Tamoxifen + Goserelin (Oral + Implant Regimen) – 20 mg + Depot

Tamoxifen + Goserelin combination therapy is an oral plus implant regimen used for the management of hormone receptor-positive breast cancer and certain prostate cancers, under oncologist supervision.

• Tamoxifen (20 mg, oral tablet): A selective estrogen receptor modulator (SERM) that blocks estrogen receptors in breast tissue, inhibiting cancer cell proliferation in hormone-sensitive tumors.

• Goserelin (Depot, subcutaneous implant): A Luteinizing Hormone-Releasing Hormone (LHRH) agonist that suppresses ovarian or testicular hormone production, reducing circulating estrogen or testosterone to inhibit tumor growth.

This combination is widely used in pre-menopausal women with breast cancer and in certain androgen-sensitive prostate cancers, providing enhanced efficacy by dual hormone suppression.

Each dosage form contains:

• Tamoxifen Citrate BP – 20 mg (per oral tablet)

• Goserelin Acetate BP – Depot formulation (3.6 mg/28 days or 10.8 mg/12 weeks, as per prescription)

• Excipients: q.s.

• Hormone receptor-positive breast cancer (pre- and post-menopausal women)

• Adjuvant therapy following surgery or chemotherapy

• Metastatic hormone-sensitive breast cancer

• Androgen-sensitive prostate cancer

• Neoadjuvant therapy to shrink tumors before surgery

• Combination therapy for long-term hormone suppression

• Improvement of disease-free survival in high-risk patients

• Tamoxifen: 20 mg orally once daily, as directed by the oncologist

• Goserelin Depot: Subcutaneous implant administered every 28 days (3.6 mg) or every 12 weeks (10.8 mg), depending on protocol

• Administration:

  • Tamoxifen with or without food

  • Goserelin depot by trained healthcare professional

⚠ Monitor liver function, bone density, and hormone levels regularly
⚠ Contraindicated during pregnancy and breastfeeding
⚠ Observe for hot flashes, mood changes, and injection site reactions

• Tamoxifen: Blister strips / HDPE bottles

• Goserelin: Sterile depot prefilled syringe or implant kit

• Hospital, institutional, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10DAYS
• Packaging Details: 120 tablets

CARBOTERO Injection contains Carboplatin, a platinum-based antineoplastic (anticancer) agent used in the treatment of various solid tumors. It works by interfering with DNA replication in cancer cells, thereby inhibiting their growth and proliferation. The injection is supplied as a sterile formulation for intravenous administration under strict oncological supervision.

Each vial contains:

• Carboplatin IP – 150 mg

• Water for Injection – q.s.

• Dosage Form: Injection

CARBOTERO Injection is indicated for the treatment of:

• Ovarian cancer

• Lung cancer (including non-small cell and small cell)

• Head and neck cancers

• Other solid tumors as prescribed by an oncologist

• For intravenous (IV) infusion only

• Dosage is calculated based on body surface area or renal function (Calvert formula)

• To be administered under the supervision of an oncologist or trained healthcare professional

• Platinum-based chemotherapeutic agent

• Widely used in combination chemotherapy regimens

• Effective in a range of solid tumors

• Suitable for hospital and oncology center use

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

• Strength: 150 mg

• Pack Type: Vial

• Pack Size: 1 vial

Additional Information:

• Production Capacity: 50000
• Delivery Time: 10days
• Packaging Details: 150 mg/ 15ml

CARBOTERO Injection contains Carboplatin, a platinum-based antineoplastic (anticancer) agent used in the treatment of various solid tumors. It acts by interfering with DNA synthesis and replication in cancer cells, thereby inhibiting tumor growth. The injection is intended for intravenous administration under strict medical supervision in oncology settings.

Each vial contains:

• Carboplatin IP – 450 mg

• Water for Injection – q.s.

• Dosage Form: Injection

CARBOTERO Injection is indicated for the treatment of:

• Ovarian cancer

• Lung cancer (small cell and non-small cell)

• Head and neck cancers

• Other solid tumors as advised by an oncologist

• For intravenous (IV) infusion only

• Dosage based on body surface area or renal function (Calvert formula)

• To be administered under the supervision of a qualified oncologist

• Platinum-based chemotherapy agent

• Widely used in combination regimens

• Effective against various solid tumors

• Suitable for hospital and oncology center use

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

• Strength: 450 mg

• Pack Type: Vial

• Pack Size: 1 vial

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 450 mg/45 ml

Enzalutamide Capsules 40 mg are an oral androgen receptor inhibitor indicated for the treatment of advanced prostate cancer. Enzalutamide works by blocking androgen receptor signaling at multiple steps, thereby inhibiting the growth and survival of prostate cancer cells. It is widely used in metastatic and castration-resistant prostate cancer and is administered under strict oncologist supervision.

Each capsule contains:

• Enzalutamide IP / USP – 40 mg

• Excipients – q.s.

Enzalutamide Capsules 40 mg are indicated for:

• Metastatic castration-resistant prostate cancer (mCRPC)

• Non-metastatic castration-resistant prostate cancer (nmCRPC)

• Metastatic hormone-sensitive prostate cancer (mHSPC)

• Used alone or in combination with androgen deprivation therapy (ADT)

• Dosage as prescribed by the oncologist

• Usual recommended dose: 160 mg once daily (4 capsules of 40 mg)

• Can be taken with or without food

• Capsules should be swallowed whole with water; do not open or crush

• Store below 25°C

• Protect from moisture and light

• Keep out of reach of children

• Blister strips or HDPE bottles

• Strength: 40 mg

• Pack size: As per manufacturer

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 4x7 capsules

Enzalutamide Capsules 80 mg are an oral androgen receptor inhibitor used in the treatment of advanced prostate cancer. Enzalutamide blocks androgen receptor signaling at multiple steps, thereby inhibiting tumor growth and disease progression. It is commonly prescribed for metastatic castration-resistant prostate cancer (mCRPC) as well as metastatic hormone-sensitive prostate cancer (mHSPC). The capsules are intended for oral administration under strict oncologist supervision.

Each capsule contains:

• Enzalutamide IP / USP – 80 mg

• Excipients – q.s.

Enzalutamide Capsules 80 mg are indicated for:

• Metastatic castration-resistant prostate cancer (mCRPC)

• Non-metastatic castration-resistant prostate cancer (nmCRPC)

• Metastatic hormone-sensitive prostate cancer (mHSPC)

• As monotherapy or in combination with androgen deprivation therapy (ADT)

• Dosage as prescribed by the oncologist

• Typical daily dose: 160 mg once daily (2 capsules of 80 mg) or as directed

• Can be taken with or without food

• Capsules should be swallowed whole with water; do not open or crush

• Store below 25°C

• Protect from moisture and light

• Keep out of reach of children

• Blister strips or HDPE bottles

• Strength: 80 mg

• Pack size: As per manufacturer

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 30 capsules

Pagenax 120 mg Injection is a non-steroidal anti-inflammatory drug (NSAID) containing Parecoxib Sodium, a selective COX-2 inhibitor. It is used for the short-term management of acute postoperative pain where oral therapy is not suitable. Pagenax provides effective pain relief with reduced gastrointestinal side effects compared to non-selective NSAIDs and is administered under medical supervision.

Each vial contains:

• Parecoxib Sodium equivalent to Parecoxib 120 mg

• Sterile excipients – q.s.

Pagenax 120 mg Injection is indicated for:

• Short-term treatment of acute pain

• Postoperative pain management

• Moderate to severe pain where injectable therapy is required

• Administered by intravenous (IV) or intramuscular (IM) injection

• Dosage depends on severity of pain and patient condition

• To be used only under the supervision of a registered medical practitioner

• Not recommended for long-term use

• Store below 25°C

• Protect from light

• Keep out of reach of children

Additional Information:

• Production Capacity: 100000
• Delivery Time: 10days
• Packaging Details: 120mg injection

Ibrutinib Tablets BP – 140 mg

Ibrutinib 140 mg Tablets BP is a targeted anticancer medicine belonging to the class of Bruton’s Tyrosine Kinase (BTK) inhibitors, used in the treatment of various B-cell malignancies.

Ibrutinib works by irreversibly inhibiting BTK, a key enzyme in B-cell receptor signaling, thereby blocking cancer cell survival, proliferation, and migration. It has transformed the management of chronic lymphocytic leukemia and other lymphomas due to its high efficacy and oral convenience.

Each film-coated tablet contains:

• Ibrutinib BP – 140 mg

• Excipients: q.s. (pharmaceutical grade)

Ibrutinib Tablets are indicated for:

1. Chronic Lymphocytic Leukemia (CLL)

   • Including patients with 17p deletion

2. Small Lymphocytic Lymphoma (SLL)

3. Mantle Cell Lymphoma (MCL)

   • In patients who have received at least one prior therapy

1. Waldenström’s Macroglobulinemia

2. Marginal Zone Lymphoma (MZL)

   • In patients requiring systemic therapy

3. Chronic Graft-versus-Host Disease (cGVHD)

   • After failure of one or more systemic therapies

• Dose varies by indication (e.g., 420 mg or 560 mg daily, as multiples of 140 mg)

• Taken orally once daily, with or without food

• Tablets should be swallowed whole with water

• Treatment continued until disease progression or unacceptable toxicity

• Blister packs: 10 tablets per strip

• Institutional / bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 100000
• Delivery Time: 10 days
• Packaging Details: 140 mg

Bevacizumab Ophthalmic Pre-Filled Syringe (PFS) 1.25 mg / 0.05 ml

Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby preventing abnormal blood vessel growth and vascular leakage in the eye. Although primarily approved for oncology use, ophthalmic formulations are widely used off-label for treating retinal vascular disorders such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The pre-filled syringe (PFS) ensures accurate dosing, sterile administration, and improved patient safety.

• Bevacizumab: 1.25 mg

• Excipients: Buffer, stabilizers, and BP/USP-grade excipients

Each pre-filled syringe delivers 1.25 mg in 0.05 ml for intravitreal injection.

• Neovascular (wet) age-related macular degeneration (AMD)

• Diabetic macular edema (DME)

• Macular edema following retinal vein occlusion (RVO)

• Myopic choroidal neovascularization (mCNV)

• Other VEGF-mediated retinal disorders (off-label ophthalmic use)

• Administered via intravitreal injection by a qualified ophthalmologist

• Typical dosage: 1.25 mg once every 4–6 weeks; may vary based on patient condition and response

• Strict aseptic technique required during administration

• VEGF-A inhibitor for effective control of retinal neovascularization and edema

• Pre-filled syringe for precise, ready-to-use intravitreal dosing

• Sterile, pyrogen-free, and BP/USP-compliant formulation

• Supports vision preservation and slows progression of retinal diseases

• 0.05 ml PFS containing 1.25 mg Bevacizumab

• Supplied in sterile individual packs suitable for ophthalmic use

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 1.25mg/0.5ml

Thalidomide Tablets BP – 100 mg

Thalidomide 100 mg Tablets BP is an immunomodulatory and anticancer agent widely used in the treatment of multiple myeloma and selected inflammatory conditions.

Thalidomide exhibits anti-angiogenic, immunomodulatory, and anti-inflammatory properties, helping to inhibit tumor growth, suppress cytokine production, and enhance immune response. Due to its potency, thalidomide is used under strict medical supervision.

Each tablet contains:

• Thalidomide BP – 100 mg

• Excipients: q.s. (pharmaceutical grade)

Thalidomide Tablets are indicated for:

1. Multiple Myeloma

   • In combination with dexamethasone or other agents

2. Relapsed or refractory plasma cell disorders

1. Erythema Nodosum Leprosum (ENL)

   • Severe inflammatory complication of leprosy

2. Immunomodulatory therapy in selected chronic inflammatory conditions (as prescribed)

• Typical dose: 100 mg once daily, usually taken at bedtime

• Dose may be adjusted based on response and tolerance

• Tablets should be swallowed whole with water

• Use only under specialist supervision

• Blister packs: 10 tablets per strip

• Institutional and bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 100 mg

Letrozole Tablets BP – 2.5 mg

Letrozole Tablets BP is a non-steroidal aromatase inhibitor used in the treatment of hormone-dependent breast cancer in postmenopausal women. It works by blocking the aromatase enzyme, significantly reducing estrogen production, which helps slow or stop the growth of estrogen-sensitive tumors.

Letrozole is widely prescribed as first-line therapy, adjuvant treatment, and extended adjuvant therapy for early and advanced breast cancer, offering effective long-term disease control.

Each film-coated tablet contains:

• Letrozole BP – 2.5 mg

• Excipients: q.s.

• Early breast cancer in postmenopausal women (adjuvant therapy)

• Advanced or metastatic breast cancer (hormone-receptor positive)

• First-line treatment of hormone-dependent breast cancer

• Extended adjuvant therapy following tamoxifen treatment

• Prevention of recurrence in estrogen-positive breast cancer

• Route: Oral

• Typical Dose: 2.5 mg once daily

• Administration: Can be taken with or without food

⚠ For use in postmenopausal women only
⚠ To be used strictly under oncologist supervision

• Blister / strip packaging

• Bottle packaging available

• Hospital and export-grade bulk packaging options

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 2.5 mg

Olaparib Tablets BP – 100 mg

Olaparib Tablets BP is an oral Poly (ADP-ribose) polymerase (PARP) inhibitor used in the targeted treatment of various advanced and metastatic cancers, particularly those associated with BRCA gene mutations.

Olaparib works by blocking PARP enzymes, preventing cancer cells from repairing damaged DNA, leading to selective cancer cell death while sparing normal cells. It is widely used in maintenance and monotherapy regimens for ovarian, breast, prostate, and pancreatic cancers.

Each film-coated tablet contains:

• Olaparib BP – 100 mg

• Excipients: q.s.

• Maintenance treatment of platinum-sensitive recurrent ovarian cancer

• Advanced ovarian cancer with BRCA1/BRCA2 mutation

• HER2-negative metastatic breast cancer with germline BRCA mutation

• Metastatic castration-resistant prostate cancer (mCRPC) with HRR gene mutation

• Metastatic pancreatic adenocarcinoma with germline BRCA mutation

• Maintenance therapy after response to platinum-based chemotherapy

• Targeted therapy in homologous recombination-deficient (HRD) tumors

• Route: Oral

• Usual Dose: As prescribed by oncologist (commonly twice daily dosing)

• Administration: Can be taken with or without food

⚠ Treatment should be initiated and monitored by a cancer specialist
⚠ Regular blood counts and renal function monitoring required

• Blister packs / HDPE bottles

• Hospital supply and bulk export packaging available

• Store below 30°C

• Protect from moisture and light

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 120 tablets

Osimertinib Tablets BP – 80 mg

Osimertinib Tablets BP is a third-generation, irreversible Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor used in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC), including tumors with the T790M resistance mutation.

Osimertinib selectively inhibits both EGFR-sensitizing mutations and T790M mutations, while sparing wild-type EGFR. This results in effective tumor control with improved central nervous system (CNS) penetration, making it highly effective against brain metastases.

Each film-coated tablet contains:

• Osimertinib BP – 80 mg

• Excipients: q.s.

• EGFR mutation-positive non-small cell lung cancer (NSCLC)

• First-line treatment of locally advanced or metastatic NSCLC

• NSCLC with EGFR T790M mutation after progression on prior EGFR-TKI therapy

• Maintenance therapy in EGFR-responsive lung cancer

• NSCLC with brain metastases due to high CNS penetration

• Adjuvant treatment following surgical resection of EGFR-mutated NSCLC

• Advanced lung adenocarcinoma with EGFR exon 19 deletion or L858R mutation

• Route: Oral

• Usual Dose: 80 mg once daily

• Administration: With or without food; tablet may be dispersed in water if swallowing is difficult

⚠ Monitor cardiac function (QT interval) and lung symptoms
⚠ Dose modification may be required based on tolerability

• Blister strips / HDPE bottles

• Hospital and export-oriented packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 120 tablets

LEUCORIN Injection contains Leucovorin Calcium, a reduced form of folic acid used mainly as a rescue therapy in patients receiving high-dose methotrexate and as an adjunct in certain cancer chemotherapy regimens. It is also indicated in the treatment of folate deficiency and megaloblastic anemia where oral therapy is not feasible. The injection is supplied as a sterile solution for intravenous or intramuscular administration under medical supervision.

Each vial/ampoule contains:

• Leucovorin Calcium IP – strength as per label

• Water for Injection – q.s.

• Dosage Form: Injection

(Common strengths: 50 mg, 100 mg – can be customized as per your product)

LEUCORIN Injection is used for:

• Methotrexate rescue therapy

• Adjunct therapy in colorectal cancer chemotherapy (with 5-FU)

• Treatment of folate deficiency

• Megaloblastic anemia (when oral therapy is unsuitable)

• Reduction of toxicity of certain folic acid antagonist drugs

• Administered by IV or IM route

• Dosage and schedule depend on indication and patient condition

• To be used strictly under the supervision of an oncologist or registered medical practitioner

• Reduced folate formulation

• Essential supportive care in chemotherapy

• Helps minimize methotrexate toxicity

• IP grade, hospital-use injectable

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

• Dosage Form: Injection

• Pack Type: Vial / ampoule

• Strength: As per label claim

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 50mg/5ml

Letrozole Tablets contain Letrozole, a non-steroidal aromatase inhibitor used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Letrozole works by inhibiting the aromatase enzyme, reducing estrogen production, and thereby slowing the growth of estrogen-dependent breast tumors. The tablets are intended for oral administration under strict medical supervision.

Each film-coated tablet contains:

• Letrozole IP – 2.5 mg

• Excipients – q.s.

• Dosage Form: Film-coated tablet

Letrozole Tablets are indicated for:

• Hormone receptor-positive breast cancer in postmenopausal women

• Adjuvant or neoadjuvant therapy in breast cancer

• Treatment of advanced or metastatic breast cancer as prescribed by an oncologist

• For oral use only

• Typical dosage: 2.5 mg once daily, or as prescribed by a registered medical practitioner

• Tablets should be taken at the same time each day, with or without food

• Swallow tablets whole; do not crush or chew

• Aromatase inhibitor for targeted breast cancer therapy

• Effective in postmenopausal hormone receptor-positive cases

• IP-grade formulation

• Suitable for hospital, oncology, and outpatient use

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Strength: 2.5 mg

• Dosage Form: Film-coated tablet

• Pack Size: As per label (e.g., 10/30 tablets per strip)

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 3x10 tablets

Trastuzumab Injection 150 mg is a humanized monoclonal antibody used for the treatment of HER2-positive breast and gastric cancers. It works by targeting the HER2 receptor on cancer cells, inhibiting cell proliferation and inducing immune-mediated cytotoxicity. The injection is supplied as a sterile, clear solution for intravenous infusion and must be administered under specialist supervision.

Each vial contains:

• Trastuzumab IP – 150 mg

• Excipients – q.s.

Trastuzumab Injection 150 mg is indicated for:

• HER2-positive breast cancer (early and metastatic)

• HER2-positive gastric or gastroesophageal junction adenocarcinoma

• Can be used alone or in combination with chemotherapy as prescribed by an oncologist

• Administered by intravenous infusion following recommended dilution guidelines

• Dosage and schedule depend on patient weight, cancer type, and treatment protocol

• Patients must be monitored for cardiac function and infusion-related reactions

• Store at 2°C to 8°C (refrigerated)

• Protect from light

• Do not freeze

• Do not shake vigorously

• Vial

• Strength: 150 mg

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 150 mg

Thalidomide Capsules contain Thalidomide, an immunomodulatory and anti-angiogenic agent used primarily in the treatment of multiple myeloma and certain inflammatory and dermatological conditions. Thalidomide works by modulating immune responses, inhibiting angiogenesis, and suppressing tumor necrosis factor-alpha (TNF-α). Due to its known teratogenic effects, Thalidomide must be used strictly under controlled medical supervision.

Each hard gelatin capsule contains:

• Thalidomide USP – 50 mg

• Excipients – q.s.

• Dosage Form: Capsule

Thalidomide Capsules are indicated for:

• Multiple myeloma (in combination with other anticancer agents)

• Erythema nodosum leprosum (ENL)

• Other immunological or oncological conditions as prescribed by a specialist

• For oral use only

• Dosage and treatment duration strictly as directed by a registered medical practitioner

• Capsules should be swallowed whole with water, preferably at bedtime

• Do not open, break, or chew the capsule

• Immunomodulatory and anti-angiogenic action

• Effective in hematological malignancies

• USP-grade formulation

• Intended for use under strict medical and regulatory control

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Strength: 50 mg

• Dosage Form: Capsule

• Pack Size: As per label (e.g., 10 / 28 capsules per strip or bottle

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 10x10 tablets

Thalidomide Capsules contain Thalidomide, an immunomodulatory and anti-angiogenic agent widely used in the treatment of multiple myeloma and certain severe inflammatory conditions. It acts by modulating immune responses, inhibiting angiogenesis, and suppressing tumor necrosis factor-alpha (TNF-α). Due to its potent teratogenic potential, Thalidomide must be used only under strict medical supervision and regulatory controls.

Each hard gelatin capsule contains:

• Thalidomide USP – 100 mg

• Excipients – q.s.

• Dosage Form: Capsule

Thalidomide Capsules are indicated for:

• Multiple myeloma (in combination with other anticancer agents)

• Erythema nodosum leprosum (ENL)

• Other immunological or oncological conditions as prescribed by a specialist

• For oral use only

• Dosage and duration strictly as directed by a registered medical practitioner

• Capsules should be swallowed whole with water, preferably at bedtime

• Do not open, break, or chew the capsule

• Immunomodulatory and anti-angiogenic action

• Effective in hematological malignancies

• USP-grade formulation

• Intended for controlled use under specialist supervision

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Strength: 100 mg

• Dosage Form: Capsule

• Pack Size: As per label (e.g., 10 / 28 capsules per strip or bottle)

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 10x10 Capsules

Lenalidomide Capsules contain Lenalidomide, an immunomodulatory and antineoplastic agent used in the treatment of certain hematological malignancies. It works by modulating the immune system, inhibiting angiogenesis, and inducing apoptosis of malignant cells. Lenalidomide is commonly used in multiple myeloma and specific myelodysplastic syndromes, under strict oncological supervision.

Each hard gelatin capsule contains:

• Lenalidomide IP – 5 mg

• Excipients – q.s.

• Dosage Form: Capsule

Lenalidomide Capsules are indicated for the treatment of:

• Multiple myeloma (in combination with other agents)

• Myelodysplastic syndromes (MDS) associated with deletion 5q abnormality

• Certain lymphomas, as prescribed by an oncologist

• For oral use only

• Dosage and treatment cycle determined by a registered medical practitioner

• Capsules should be swallowed whole with water

• Do not open, break, or chew the capsule

• Immunomodulatory and anti-cancer agent

• Widely used in hematological malignancies

• IP-grade formulation

• Suitable for hospital and specialty oncology use

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Strength: 5 mg

• Dosage Form: Capsule

• Pack Size: As per label (e.g., 10 / 21 capsules per strip or bottle)

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 10 tablets

Lenalidomide Capsules contain Lenalidomide, an immunomodulatory and antineoplastic agent used in the treatment of various hematological malignancies. It acts by enhancing immune-mediated tumor cell death, inhibiting angiogenesis, and suppressing the growth of malignant cells. Lenalidomide is widely used in multiple myeloma and selected myelodysplastic syndromes under strict oncological supervision.

Each hard gelatin capsule contains:

• Lenalidomide IP – 25 mg

• Excipients – q.s.

• Dosage Form: Capsule

Lenalidomide Capsules are indicated for the treatment of:

• Multiple myeloma (as monotherapy or in combination therapy)

• Myelodysplastic syndromes (MDS) associated with deletion 5q abnormality

• Certain lymphomas, as prescribed by an oncologist

• For oral use only

• Dosage and treatment cycle determined by a registered medical practitioner

• Capsules should be swallowed whole with water

• Do not open, break, or chew the capsule

• Immunomodulatory anticancer agent

• Widely used in hematological malignancies

• IP-grade formulation

• Suitable for hospital and specialty oncology use

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Strength: 25 mg

• Dosage Form: Capsule

• Pack Size: As per label (e.g., 10 / 21 capsules per strip or bottle)

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 10 capsule

Trastuzumab Injection 440 mg is a humanized monoclonal antibody designed for the treatment of HER2-positive breast and gastric cancers. It selectively targets the HER2 receptor on cancer cells, inhibiting tumor cell proliferation and inducing immune-mediated cytotoxicity. The injection is supplied as a sterile, clear solution for intravenous infusion and must be administered under the supervision of an oncologist.

Each vial contains:

• Trastuzumab IP – 440 mg

• Excipients – q.s.

Trastuzumab Injection 440 mg is indicated for:

• HER2-positive breast cancer (early and metastatic)

• HER2-positive gastric or gastroesophageal junction adenocarcinoma

• Can be used as monotherapy or in combination with chemotherapy as per oncologist’s prescription

• Administered via intravenous infusion after appropriate dilution

• Dosage and schedule depend on patient weight, cancer type, and treatment protocol

• Patients must be monitored for cardiac function and infusion-related reactions during and after administration

• Store at 2°C to 8°C (refrigerated)

• Protect from light

• Do not freeze

• Do not shake vigorously

• Single-dose vial

• Strength: 440 mg

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 400mg

Cetrorelix Acetate Injection 0.25 mg is a synthetic gonadotropin-releasing hormone (GnRH) antagonist used in assisted reproductive technology (ART) protocols. It works by inhibiting premature luteinizing hormone (LH) surge, allowing controlled ovarian stimulation in women undergoing fertility treatments. The injection is intended for subcutaneous administration under strict medical supervision.

Each vial/ampoule contains:

• Cetrorelix Acetate IP / USP – 0.25 mg

• Sterile water or suitable vehicle – q.s.

• Excipients – q.s.

Cetrorelix Acetate Injection 0.25 mg is indicated for:

• Prevention of premature LH surge in controlled ovarian stimulation (COS) protocols

• Used in in vitro fertilization (IVF) and other ART procedures

• Optimizes follicular development and oocyte retrieval timing

• Administered subcutaneously as prescribed by the fertility specialist

• Common dose: 0.25 mg once daily during ovarian stimulation

• Use aseptic technique for injection

• Dosage and duration depend on patient response and ART protocol

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Do not freeze

• Available in vials or prefilled syringes

• Strength: 0.25 mg per vial/ampoule

• Pack size: As per manufacturer

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 0.25 mg

Acalabrutinib Capsules 100 mg is an oral anticancer medication belonging to the class of Bruton’s Tyrosine Kinase (BTK) inhibitors. It is used in the management of certain types of blood cancers and works by blocking BTK activity, thereby inhibiting the growth and survival of malignant B-cells. This medicine is to be used strictly under the supervision of a qualified oncologist or healthcare professional.

• Active Ingredient:
  Acalabrutinib – 100 mg

• Excipients:
  q.s.

• Dosage Form:
  Hard gelatin capsules

Acalabrutinib Capsules are indicated for the treatment of:

• Chronic Lymphocytic Leukemia (CLL)

• Small Lymphocytic Lymphoma (SLL)

• Other BTK-responsive lymphoid malignancies as prescribed by a doctor

(Prescription medicine – oncology use only)

• Dosage as directed by an oncologist

• Capsules should be swallowed whole with water

• Do not open, crush, or chew the capsule

• Treatment duration depends on patient response and clinical condition

• Store below 25°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

• For prescription use only

• Not recommended during pregnancy and breastfeeding

• Use with caution in patients with bleeding disorders or cardiac conditions

• Regular medical monitoring is required during therapy

• Strip or bottle pack (as available)

• Commercial hospital and pharmacy supply

• Manufactured in compliance with GMP standards

• Quality tested for purity, safety, and efficacy

• India

Additional Information:

• Production Capacity: 250000
• Delivery Time: 10days
• Packaging Details: 30 Capsules

Acalabrutinib Capsules 100 mg are a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By selectively inhibiting BTK, acalabrutinib prevents malignant B-cell proliferation and survival, offering targeted therapy with improved safety profiles. The capsules are intended for oral administration under strict medical supervision.

Each capsule contains:

• Acalabrutinib IP – 100 mg

• Excipients – q.s.

Acalabrutinib Capsules 100 mg are indicated for:

• Chronic lymphocytic leukemia (CLL)

• Small lymphocytic lymphoma (SLL)

• Mantle cell lymphoma (MCL)

• Use in patients with relapsed or refractory disease as prescribed by an oncologist

• Dosage as prescribed by the physician

• Usually taken twice daily with or without food

• Swallow capsules whole; do not crush, chew, or open

• Store below 25°C

• Protect from moisture and light

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 100 mg

Lenalidomide Capsules contain Lenalidomide, an immunomodulatory and antineoplastic agent used in the treatment of certain hematological malignancies. It works by modulating immune response, inhibiting angiogenesis, and inducing apoptosis in malignant cells. Lenalidomide is widely prescribed in multiple myeloma and selected myelodysplastic syndromes, under strict oncological supervision.

Each hard gelatin capsule contains:

• Lenalidomide IP – 10 mg

• Excipients – q.s.

• Dosage Form: Capsule

Lenalidomide Capsules are indicated for the treatment of:

• Multiple myeloma (as monotherapy or in combination therapy)

• Myelodysplastic syndromes (MDS) associated with deletion 5q abnormality

• Certain lymphomas, as prescribed by an oncologist

• For oral use only

• Dosage and treatment cycle determined by a registered medical practitioner

• Capsules should be swallowed whole with water

• Do not open, break, or chew the capsule

• Immunomodulatory anticancer agent

• Effective in hematological malignancies

• IP-grade formulation

• Suitable for hospital and specialty oncology use

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Strength: 10 mg

• Dosage Form: Capsule

• Pack Size: As per label (e.g., 10 / 21 capsules per strip or bottle)

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 10 capsule

Propofol Injection IP 200 mg/20 ml is a sterile intravenous anesthetic agent used for the induction and maintenance of general anesthesia and sedation. It provides rapid onset and quick recovery, making it ideal for surgical procedures, intensive care sedation, and outpatient anesthesia. This injection should be administered only under the supervision of trained healthcare professionals.

• Active Ingredient:
  Propofol – 200 mg / 20 ml (10 mg/ml)

• Excipients:
  Soybean oil, glycerol, egg lecithin, sodium hydroxide, water for injection

• Dosage Form:
  Sterile injectable emulsion

Propofol Injection is indicated for:

• Induction of general anesthesia

• Maintenance of anesthesia during surgery

• Sedation of mechanically ventilated patients in intensive care units

• Procedural sedation in minor surgical or diagnostic procedures

(Prescription medicine – hospital and clinical use only)

• Administered intravenously by trained healthcare professionals

• Dose depends on patient age, weight, clinical condition, and procedure

• Continuous monitoring of respiratory and cardiovascular status is required

• Not for intramuscular use

• Store below 25°C

• Protect from light and heat

• Keep the vial tightly closed

• Keep out of reach of children

• For prescription use only

• Use with caution in patients with cardiac, respiratory, or hepatic impairment

• Monitor vital signs continuously during administration

• Not recommended during pregnancy unless clearly indicated

• 20 ml vial containing 200 mg Propofol

• Supplied with protective outer carton

• Manufactured in compliance with IP and GMP guidelines

• Tested for sterility, potency, and safety

• India

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 200mg/2ml

Acaone Capsules contain Acitretin 100 mg, a systemic retinoid used in the treatment of severe psoriasis and other disorders of keratinization. Acitretin works by normalizing skin cell growth and reducing inflammation, helping to improve skin lesions in chronic dermatological conditions. Acaone Capsules should be used strictly under the supervision of a qualified dermatologist.

• Active Ingredient:
  Acitretin – 100 mg per capsule

• Excipients:
  q.s.

• Dosage Form:
  Hard gelatin capsule

Acaone 100 mg Capsules are indicated for:

• Severe psoriasis (including erythrodermic and pustular psoriasis)

• Disorders of keratinization

• Other severe dermatological conditions as prescribed by a dermatologist

(Prescription medicine – use only under medical supervision)

• Dosage as prescribed by the dermatologist

• Usually taken orally with meals

• Capsule should be swallowed whole with water

• Regular monitoring is required during treatment

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 30 Capsules

Jogren Tablets contain Pilocarpine Hydrochloride 5 mg, a cholinergic agonist used to stimulate secretion of saliva and sweat. It is primarily prescribed for the treatment of dry mouth (xerostomia) associated with Sjögren’s syndrome and for patients experiencing reduced salivary flow due to radiotherapy for head and neck cancer. The medication should be used under medical supervision.

• Active Ingredient:
  Pilocarpine Hydrochloride – 5 mg per tablet

• Excipients:
  q.s.

• Dosage Form:
  Film-coated tablets

• Pharmacopoeial Standard:
  IP / USP (as applicable)

Pilocarpine Hydrochloride Tablets are indicated for:

• Management of dry mouth (xerostomia) due to Sjögren’s syndrome

• Radiation-induced salivary gland hypofunction

• As prescribed by a physician

(Prescription medicine – use only under medical supervision)

• Dosage as directed by the treating physician

• Tablets should be taken orally with water

• May be taken with or without food

• Adequate hydration is recommended during therapy

• Store below 30°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

• For prescription use only

• Use with caution in patients with asthma, cardiovascular disease, or glaucoma

• Not recommended during pregnancy or breastfeeding unless prescribed

• Excessive sweating may occur; maintain fluid intake

• Strip or bottle packing (as available)

• Suitable for hospital, pharmacy, and distributor supply